The new data was presneted at the 2025 San Antonio Breast Cancer Symposium
Wobble Genomics, a biotechnology company specialising in improving cancer outcomes through better diagnosis and therapy selection, presented new data at the 2025 San Antonio Breast Cancer Symposium (SABCS), held on December 9-12 in San Antonio, Texas.
The presentation, titled ‘Isoform Level RNA Detection Provides More Detailed Profiling of HER2 Expression in Breast Cancer’, was given on December 11 and revealed the ability to accurately detect HER2 expression in breast cancer, in both solid tumour biopsies and blood samples.
The new data confirm the platform’s ability to determine HER2 status with high fidelity from breast cancer tissue, deliver detailed isoform-level profiles, and show a correlation with HER2 immunohistochemistry (IHC) scores. The study also established the potential of Wobble’s long-read RNA technology to select HER2-targeted therapy from blood.
These findings deliver insights into transcript diversity and expression patterns, allowing improved diagnostic accuracy and refining therapy selection. This will enable a more precise understanding of tumour biology, facilitating better-informed decisions when determining the most appropriate therapy for breast cancer patients.
Dr Richard Kuo, CEO and founder of Wobble Genomics, said, “Our research highlights the significant promise of our platform, offering a new level of precision in cancer diagnostics by providing detailed isoform-level insights into HER2 expression. These findings could enable clinicians to make more informed therapy choices, leading to safer, more personalised care for patients.”
